Krystal Biotech, Inc.
Krystal Biotech, Inc. (KRYS): 12 pipeline candidates · 1 upcoming catalyst · ~42 mo cash runway · 9 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
41.5 months
D/E 0.09 · 4% dilution
Lead: Phase 3
12 candidates
1 upcoming, next in ~166d
0 buys · 75 sells (180d)
A transparent, data-derived signal for Krystal Biotech, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$10.1B
Cash
$501.3M
Quarterly Burn
$62.7M
Runway
41.5 mo
Revenue
$116.4M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (12 candidates)
| Drug | Phase |
|---|---|
| chemotherapy | Phase 1/Phase 2 |
| kb301 | Phase 1 |
| kb304 | Phase 1/Phase 2 |
| kb407 | Phase 1/Phase 2 |
| KB407 | Phase 1 |
| KB407 | Phase 1/Phase 2 |
| kb408 | Phase 1 |
| kb707 | Phase 1/Phase 2 |
| kb801 | Phase 1/Phase 2 |
| kb803 | Phase 3 |
Showing 10 of 12 candidates. Sign up for full pipeline.
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
364
Total value held
$6.23B
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 4,373,987 | $1.13B |
| blackrock, inc. | 3,940,456 | $1.02B |
| vanguard capital management llc | 2,330,648 | $602.1M |
| vanguard portfolio management llc | 1,456,727 | $376.3M |
| state street corp | 1,314,434 | $339.5M |
| geode capital management, llc | 643,975 | $166.4M |
| hood river capital management llc | 619,586 | $160.1M |
| janus henderson group plc | 533,318 | $137.8M |
| bellevue group ag | 481,785 | $124.5M |
| frazier life sciences management, l.p. | 481,307 | $124.3M |
Showing top 10 of 364 institutional holders of Krystal Biotech, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Krystal Biotech, Inc.'s pipeline?
Krystal Biotech, Inc. (KRYS) has 12 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Krystal Biotech, Inc.'s lead drug candidate?
Krystal Biotech, Inc.'s most advanced tracked candidate is chemotherapy (Phase 1/Phase 2) for Lung Cancer, Non-small Cell.
What is Krystal Biotech, Inc.'s next catalyst?
Krystal Biotech, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Double-Blind Crossover of KB803 and Matched Placebo for the Treatment and Prevention of Corneal Ab" — expected December 1, 2026.
What is Krystal Biotech, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Krystal Biotech, Inc. has approximately 41.5 months of cash runway.
What is Krystal Biotech, Inc.'s market capitalization?
Krystal Biotech, Inc.'s market capitalization is approximately $10.1B.
Get the full picture on Krystal Biotech, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.